Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization ’s database
Conclusion: These findings suggest that in females treated for breast cancer, all ETs may be associated with NCI. However, amongst iCDK4/6s, NCI may be specific to palbociclib. NCI most frequently involved learning and memory as well as language. Neurocognitive impact of treatments requires better consideration and management.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Arimidex | Brain | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | Endocrine Therapy | International Medicine & Public Health | Learning | Neurology | Study | Tamoxifen | Universities & Medical Training | WHO